Merit Medical heads into its third-quarter report with something it has not had in years: momentum that management is openly excited about. Organic constant-currency growth hit 9% last quarter, the best showing in three years, after a sluggish 3.7% in the first quarter. The question now is whether that surge marks a durable new pace or a rebound quarter flattered by a snapback in the OEM business. Thursday's numbers, due after the close on October 29, should go a long way toward settling that debate.

The Street is looking for non-GAAP earnings of $1.04 per share on revenue of $410.4 million. That revenue figure implies roughly 6.8% growth from the year-ago $384.2 million, solid but not spectacular, while the earnings estimate would represent a sizable jump from the $0.79 earned a year ago. The Earnings Whisper sits higher at $1.11, a meaningful gap that suggests the informal bar is above the published one. Both figures sit a bit below last quarter's $1.08 and $418.8 million, which squares with management's warning that the third quarter is seasonally softer, with organic growth guided to 7% to 8% and operating margin to a fairly wide 19.6% to 21.5%.

The guidance picture is what makes the setup unusual. Management lifted its full-year non-GAAP EPS outlook to $4.25 to $4.35, up from $4.01 to $4.15, and raised revenue guidance to $1.631 billion to $1.643 billion. Yet consensus still reads $4.05 for EPS and $1.62 billion for revenue, below the low end of both ranges. That disconnect looks more like estimates lagging the raise, or lingering skepticism, than a considered view that Merit will fall short. Either way, it leaves room for upside if the company simply executes its own plan. Notably, the last raise only passed through the first-half beat without lifting the back half, which is a conservative posture that makes another beat-and-raise more attainable.

Several operating threads will determine whether the story holds. OEM swung from a 14% decline to a 15% gain and management expects mid-to-high single-digit growth going forward; a relapse there would undercut the claim that the second quarter reflected broad strength rather than timing. Therapeutic products grew nearly 12% organically, and the newly launched breast-care franchise, combining ScoutMD from late May with the July U.S. launch of OneMark, is the catalyst to probe. Management framed the pairing as expanding its addressable oncology market three to four times to about 1.3 million procedures, so early commentary on adoption and account wins matters more than the dollars this quarter. Investors should also look for renal to continue recovering from the first-quarter recall, BioLife to track toward its upgraded run rate of about $23 million, and gross margin to stay near the 54% level seen last quarter despite tariff costs now pegged at $16 million for the year.

Sentiment has warmed noticeably, shifting from modestly bearish before the last report to modestly bullish now. The stock has gained about 4% since the prior report, edging out the S&P 500, but that understates the move. Shares climbed from below $60 to above $83 in the prior quarter and now trade near $91, roughly 19% above the 200-day moving average and within about 1% of the post-earnings high of $92.26. A stock testing a breakout into the print means good news is partly anticipated.

The central issue is sustainability. If Merit lands organic growth inside or above its 7% to 8% target, holds margins through tariff noise, and shows early traction in breast care, the second quarter starts to look like a baseline and the gap between consensus and guidance should close upward. A miss on OEM or a cautious fourth-quarter tone would instead suggest the acceleration was more episodic than management implied.